NNVC NanoViricides, Inc. (NYSE:NNVC) is a clinical-stage biopharmaceutical company developing a new class of broad-spectrum ...

Institutional clients can use cUSDO, OpenEden Digital’s yield-bearing digital asset, as collateral on MirrorRSV while ...

British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...

Frailty was a significant predictor of severe outcomes and hospitalization characteristics in older adults hospitalized with RSV infection.

Each year, almost 200,000 adults 65 and older are hospitalized due to RSV, and an estimated 14,000 of those cases result in ...

Shifts in RSV testing methodology, which were accelerated by changes related to the COVID-19 pandemic, mirror shifts seen in ...

“Appropriate people at higher risk should be vaccinated, and this will not only benefit the vaccinated person, but will ...

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...

Arexvy is currently approved to prevent lower respiratory tract disease (LRTD) caused by RSV in individuals aged 60 years and older, and those 50 to 59 years of age who are at increased risk for LRTD ...

In biology textbooks and beyond, the human genome and DNA therein typically are taught in only one dimension. While it can be ...

GSK plc GSK announced that the FDA has accepted its regulatory filing seeking to expand the use of its RSV vaccine, Arexvy, in adults under 50 who are at a higher risk of the disease. A final decision ...

THE arrival of Aldi in 1991, and Lidl the following year, was just the kind of kick up the rear the Irish retail market ...